HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays.

AbstractBACKGROUND:
PsA-TT (MenAfriVac) is a conjugated polysaccharide vaccine developed to eliminate group A meningococcal disease in Africa. Vaccination of African study participants with 1 dose of PsA-TT led to the production of anti-A polysaccharide antibodies and increased serum bactericidal activity measured using rabbit complement (rSBA). Bactericidal responses measured with human complement (hSBA) are presented here.
METHODS:
Sera collected before and at 28 days and 1 year after vaccination with either PsA-TT or quadrivalent polysaccharide vaccine (PsACWY) from a random, age-distributed 360-subject subset of the Meningitis Vaccine Project study of PsA-TT in Africans aged 2-29 years were tested for hSBA. Geometric mean titer, fold-rise, and threshold analyses were compared between vaccine groups and age groups. hSBA, rSBA, and immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA) results were compared and assay correlation and agreement determined.
RESULTS:
hSBA responses to PsA-TT were substantially higher than those to PsACWY at 28 days and 1 year following immunization, similar to previously reported rSBA and IgG results. The hSBA and IgG ELISA results identified differences between age groups that were not evident by rSBA. The rSBA data indicated sustained high titers 1 year after immunization, whereas hSBA GMTs at 1 year approached 4 in young children.
CONCLUSIONS:
The high level of protection following PsA-TT immunization campaigns is consistent with the strong hSBA immune responses observed here. Future implementation decisions will likely depend on immunologic data and their long-term correlation with disease and carriage prevention. Expanded immunologic and epidemiologic surveillance may improve the interpretation of differences between these immunoassays.
AuthorsGregory A Price, Aimee M Hollander, Brian D Plikaytis, Brian T Mocca, George Carlone, Helen Findlow, Ray Borrow, Samba O Sow, Aldiouma Diallo, Olubukola T Idoko, Godwin C Enwere, Cheryl Elie, Marie-Pierre Preziosi, Prasad S Kulkarni, Margaret C Bash
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 61 Suppl 5 Pg. S554-62 (Nov 15 2015) ISSN: 1537-6591 [Electronic] United States
PMID26553688 (Publication Type: Comparative Study, Journal Article)
CopyrightPublished by Oxford University Press for the Infectious Diseases Society of America 2015. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Chemical References
  • Antibodies, Bacterial
  • Immunoglobulin G
  • MenACWY-CRM vaccine
  • MenAfriVac
  • Meningococcal Vaccines
  • Complement System Proteins
Topics
  • Adolescent
  • Adult
  • Africa
  • Animals
  • Antibodies, Bacterial (blood)
  • Blood Bactericidal Activity
  • Child
  • Child, Preschool
  • Complement System Proteins
  • Humans
  • Immunoassay (methods)
  • Immunoglobulin G (blood)
  • Meningococcal Vaccines (administration & dosage, immunology)
  • Neisseria meningitidis, Serogroup A (immunology)
  • Rabbits
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: